摘要
目的:研究益生菌联合美沙拉嗪治疗炎症性肠病的效果。方法:2019年7月-2020年7月收治炎症性肠病患者80例,抽样法分为两组,各40例。对照组采用美沙拉嗪治疗;观察组采用美沙拉嗪联合益生菌治疗。比较两组治疗效果。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05);观察组治疗后TNF-α、IFN-γ及IL-8等血清炎症因子指标水平均明显低于对照组,差异有统计学意义(P<0.05)。结论:联合应用益生菌及美沙拉嗪治疗炎症性肠病,可提升临床治疗有效率,同时降低机体炎症因子水平,安全性较高。
Objective:To study the effect of probiotics combined with mesalazine in the treatment of inflammatory bowel disease.Methods:From July 2019 to July 2020,80 cases of patients with inflammatory bowel disease were enrolled,they were divided into two groups according to sampling method,with 40 cases in each group.The control group was treated with mesalazine.The observation group was treated with mesalazine combined with probiotics.The therapeutic effects between the two groups was compared.Results:The total effective rate of treatment in observation group was higher than that in control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,the difference was statistically significant(P<0.05).After treatment,the indicators levels of serum inflammatory factors such as TNF-α,IFN-γand IL-8 in the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Probiotics combined with mesalazine in the treatment of inflammatory bowel disease,which can not only improve the effective rate of clinical treatment,but also can reduce the level of inflammatory factors with high safety.
作者
廖罗罡睿
Liaoluo Gangrui(Department of Gastroenterology,the Fourth People's Hospital of Chenzhou City,Hunan Chenzhou 423000)
出处
《中国社区医师》
2021年第16期34-35,共2页
Chinese Community Doctors
关键词
益生菌
美沙拉嗪
炎症性肠病
Probiotics
Mesalazine
Inflammatory bowel disease
